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explain these findings because these were similar between the
groups.
Current risk stratification scores do not use BGL as a prognostic
variable. Our findings demonstrate a two- to four-fold increased
risk of death with high or low BGL after STEMI, highlighting an
additive prognostic value to such models. Specifically, a BGL 81
mg/dl was associated with a 3-fold increased risk of death at 30
days (p  0.01), whereas hypoglycemic patients with a TRS 4,
had a 11-fold increased risk of death.
Although the Diabetic Insulin-Glucose Infusion in Acute
Myocardial Infarction (DIGAMI)-2 trial showed no advantage for
intensive glucose management (8), a need to identify high-risk
patients with abnormal glucose metabolism remains. The negative
results may reflect improved overall management of patients
identified as high-risk. The effect of treating BGL abnormalities
was not assessed in this study, but an understanding of the
mechanisms leading to adverse outcomes with mild hyperglycemia
or hypoglycemia in the STEMI population could perhaps lead to
novel metabolic therapies to improve outcomes.
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Letters to the Editor
Frequency of Cardiac Troponin
I Mutations in Families With
Hypertrophic Cardiomyopathy in China
I read with interest the recent study on the frequency of cardiac
troponin I (cTnI) mutations in families with hypertrophic cardio-
myopathy (HCM) reported from the United Kingdom (1). It is
amazing to note that the prevalence of cTnI mutations in the United
Kingdom (3.1%) is almost identical to that in China (3%) (2).
My colleagues from Nanjing (formerly Nanking), China (2),
studied 71 patients with HCM, 45 male and 26 female, ranging in
age from 10 to 77 years (average age, 45.5  17.2 years). Exons 7
and 8 of cTnI gene of the 71 patients and 100 normal controls
were amplified by polymerase chain reaction (PCR), and the
products of PCR were analyzed by direct sequencing. Two
mutations of cTnI were identified in 71 patients with HCM (3%)
but not in the normal controls. Pedigree investigation showed
another carrier in each family: the cTnIR145W mutation carrier
had no clinical abnormalities, and the cTnIR162Q carrier had
atrial fibrillation when he was in his 20s. Further animal work
using recombinant cTnIR145W transduction into cultured mouse
adult cardiomyocytes is in progress (2).
Therefore, as Maron (3) recently noted, HCM is indeed an
important global disease. Not only is the prevalence of HCM in
China (0.16%) (4,5) almost the same as in the Western world
(0.2%, according to the Coronary Artery Risk Development In
Young Adults [CARDIA] study [6]), but the frequency rates of
cTnI mutations are the same (3%) (1,2). This low frequency is
consistent with that reported from other countries (5%) (5,7).
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We thank Dr. Cheng for his interest in our work (1) and
appreciate his comments. The prevalence of hypertrophic cardio-
myopathy (HCM) appears similar among different racial groups.
Population studies comprising more than 16,000 subjects from
Japan, China, and the U.S. (Caucasian, African, and native
Americans) have established that unexplained left ventricular (LV)
wall thickness 15 mm occurs with a prevalence of about 0.2%
(range 0.16% to 0.23%) (2–5). Recent genotype–phenotype studies
have revealed that the disease expression of HCM is extremely
heterogeneous and that many gene carriers present with electro-
cardiographic (ECG) abnormalities in the absence of LV hyper-
trophy on echocardiography. It is likely, therefore, that the true
prevalence of HCM is well above 0.2% (1). Furthermore, the
prevalence of HCM appeared to be similar in each of the screening
studies despite considerable age differences in the study popula-
tions, which suggests that HCM may develop independent of age.
This finding is in contrast to previous assumptions that HCM
develops during adolescence and early adulthood. If this was the
case, the prevalence would be age-dependent and expected to be
high at young ages and low at older ages owing to increased
mortality rates associated with HCM. Apparently, the number of
individuals dying equals the number of individuals developing the
condition at any age, resulting in a “steady-state” and age-
independent prevalence of the condition.
The frequency of mutations in the gene for cardiac troponin I
(TNNI3) has been reported in six larger studies (6–9). A total of
1,697 HCM patients have been investigated (range: 71 to 748
patients), with an average frequency of TNNI3 mutations of 2.7%
(range 0.9% to 4.0%). The studies were conducted in patients in
Great Britain, the U.S., France, China, Japan, Korea, and Ger-
many. The modest differences in frequency of mutations are most
likely explained by differences in sample sizes of patients and do
not appear to be associated with race.
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Impact of Carvedilol Before
Angiotensin-Converting Enzyme
Inhibitor Therapy on Cardiac Function
The study by Sliwa et al. (1) is indeed an eye-opener for those who
depend on expert opinions such as those from the American
College of Cardiology/American Heart Association guidelines
(1,2). However, despite a well-executed study, I am not sure the
conclusions drawn by the editor and investigators are entirely on
the mark. My main criticism is that this is a “how-to” treat and not
a “what to” treat study, and as a result it cannot ignore practicality
issues. In clinical practice, how often do we see 78 consecutive
newly diagnosed patients with New York Heart Association
(NYHA) functional classification II to IV go directly to oral
anticongestive therapy without the need for parenteral vasodilator
intervention initially? In these patients, is it really practical to
switch directly from parenteral therapy to oral beta-blockade
without the support of an afterload reducing agent? Even among
specialists, a measurable dropout rate would be expected if every
patient went straight to a beta-blocker. In fact, the concept of
using an inodilator to facilitate the commencement of a beta-
blocker in those patients who would otherwise not tolerate
adrenaline withdrawal or inhibition is for this very reason.
Conversely, concerning the control arm, are there many prac-
titioners who would wait six months before introducing a beta-
blocker? Therefore, I am surprised the researchers did not elabo-
rate on the treatment status of the subjects before they were
randomized to the carvedilol arm, and whether they encountered
difficulties during up-titration. Furthermore, as a significant num-
ber of subjects expired during the study (11 of 78, 14% after 12
months), how many required readmission for decompensation and
what happened to their beta-blocker dosing regimen?
As for the results, improved biochemical profile, NYHA func-
tional class, and echocardiographic function in the carvedilol-
initiated group would indicate that carvedilol is a more “potent”
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